Skip to main content
Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.605
+0.125 (8.45%)
At close: Mar 9, 2026, 4:00 PM EDT
1.600
-0.005 (-0.31%)
After-hours: Mar 9, 2026, 4:00 PM EDT

Metagenomi Therapeutics Revenue

In the year 2025, Metagenomi Therapeutics had annual revenue of $25.21M, down -51.79%. Metagenomi Therapeutics had revenue of $3.91M in the quarter ending December 31, 2025, a decrease of -59.32%.

Revenue (ttm)
$25.21M
Revenue Growth
-51.79%
P/S Ratio
2.35
Revenue / Employee
$203,306
Employees
124
Market Cap
60.38M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202525.21M-27.09M-51.79%
Dec 31, 202452.30M7.54M16.84%
Dec 31, 202344.76M27.56M160.21%
Dec 31, 202217.20M16.96M6,978.19%
Dec 31, 2021243.00K--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
ImmuCell 27.64M
MindWalk Holdings 19.02M
Radiopharm Theranostics 10.86M
Alterity Therapeutics 4.43M
Nutriband 2.28M
BeyondSpring 1.88M
Rallybio 674.00K
Entera Bio 124.00K
Revenue Rankings

MGX News

More News